Mr. James Parsons reports
TRILLIUM GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID PRICE RULE
Trillium Therapeutics Inc. has received a notification letter from The Nasdaq Stock Market LLC notifying the company that it is eligible for an additional 180-calendar-day period to regain compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market.
The notification has no immediate effect on the listing of the company's common shares on the exchange. The company has an additional 180 calendar days from the date of notification, which occurred on Oct. 3, 2019, or until March 30, 2020, to regain compliance with the minimum bid price requirement during which time the company's common shares will continue to trade on the exchange. If at any time before March 30, 2020, the bid price of the company's common shares closes at or above $1 (U.S.) per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the company has achieved compliance with the minimum bid price requirement.
The company intends to monitor the closing bid price of its common shares between now and March 30, 2020, and intends to cure the deficiency within the additional period provided.
The company is also listed on the Toronto Stock Exchange and the notification letter does not affect the company's compliance status with such listing.
About Trillium Therapeutics Inc.
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.